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AN ANIMAL MODEL OF AlZHEIMER'S: TIlE USE OF TIlE NEUROTOXIN 
AF64A IN COMBINATION WITH GLUCOCORTICOIDS TO DIFFERENTIATE TIlE 
IMPORTANCE OF CHOLINERGIC PATHWAYS IN LEARNING AND MEMORY. 
Gregory P. Tinkler, and Dr. Wayne Doman", Department of Psychology, IWU. 
There are approximately four million patients with Alzheimer's Disease (AD) in America 
today, with about 100,000 new cases being diagnosed every year. AD patients exhibit a 
prolonged loss of cognitive function, with learning and memory being among the first faculties 
to be affected. The pathological hallmarks of AD include senile plaques, comprised of the 
protein 13 -Amyloid. It is hypothesized that the aggregation of the 13 A protein into senile 
plaques in areas involved in learning and memory- such as the hippocampus- either causes the 
deficits seen in AD or acts synergistically to render the brain more vulnerable to insult. 
Previous efforts by our lab combining a neurotoxin with 13 A in the rat have demonstrated this, 
as well as 13 A in combination with the stress hormone corticosterone, which has been thought 
to exacerbate hippocampal damage in high levels. The deficits, however, have not been 
consistent. As an animal model of AD necessitates the dependability of these deficits, another 
possibility is being explored. The neurotransmitter system affected first and foremost in AD 
is the cholinergic system of the septohippocampal pathway. This is evidenced by a decrease 
of cholinergic markers such as choline acetyl transferase in AD brains. Much attention has 
been focused on the possibility of increasing the amounts of these cholinergic markers as a 
treatment for AD. The same premise has also been applied to the development of an animal 
model: a recent study by Hortnagl et al has demonstrated that intraventricular injections of 
a neurotoxic choline analog AF64A in combination with chronic glucocorticoid administration 
results in a decrease of cholinergic markers. This study, however, did no assessment to 
determine whether there were any resulting behavioral effects. We will attempt to expand on 
the Hortnagl study by assessing the effects on spatial learning in rats that have received 
injections of the neurotoxin AF64A and in combination with chronic stress. The Morris Water 
Maze will be used to test for behavioral deficits. The results of this study will be compared to 
another study at this conference which utilizes a highly selective cholinergic immunotoxin. 
